Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early biological therapy with methotrexate plus etanercept in poor-prognosis rheumatoid arthritis
ChiCTR2500111868Phase 4Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: ACR50 remission at 24 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500111868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111868.